GSK CEO Says 14 Billion Covid Vaccine Doses May Be Needed

The transcript discusses the collaboration between GSK and Sanofi in developing a COVID-19 vaccine. It highlights the importance of partnerships in the pharmaceutical industry, especially during the pandemic, to enhance vaccine effectiveness and scale production. The use of adjuvant technology is emphasized as a proven method to improve vaccine efficacy, particularly for older populations. The need for rapid scaling to produce billions of doses is also addressed, underscoring the challenges and strategies involved in achieving this goal.

Why did GSK choose to collaborate with Sanofi for vaccine development?

• To focus on other projects

• To leverage combined expertise against a common enemy

• To reduce costs

• To enhance vaccine effectiveness

What is the primary benefit of GSK's adjuvant technology?

• It reduces production costs

• It speeds up vaccine approval

• It eliminates the need for partnerships

• It makes vaccines more effective, especially for older people

How many doses might be needed globally if two-dose vaccines are used?

• 7 billion

• 10 billion

• 14 billion

• 20 billion

What is a significant challenge in vaccine production mentioned in the transcript?

• Achieving large-scale manufacturing

• Securing government approvals

• Finding enough raw materials

• Training new scientists

What strategy did GSK use to ensure rapid vaccine production?

• Forming partnerships

• Investing in new technology

• Hiring more staff

• Building more factories